As reported by the ISDH Long Term Care Newsletter, The Advisory Committee on Immunization Practices (ACIP) now recommends a dose of PCV13 (Prevnar 13®) in addition to the currently recommended PPSV23 (Pneumovax®) in persons 65 years and older.
Those who have not previously received pneumococcal vaccine or whose vaccination history is unknown should receive a dose of PCV13 first, followed by a dose of PPSV23 6-12 months later. The two vaccines should not be co-administered. The minimum acceptable interval between PCV13 and PPSV23 is 8 weeks.
Adults aged 65 years who have previously received 1 dose of PPSV23 and who have not yet received PCV13 should receive a dose of PCV13 at least 1 year after receipt of their most recent PPSV23 dose. When an additional dose of PPSV23 is indicated, it should be given 6 -12 months after PCV13 and 5 years after the most recent dose of PPSV23.
ACIP recommendations remain unchanged for the routine use of PCV13 in adults aged 19 years with high risk conditions including:
• immunocompromising conditions
• functional or anatomic asplenia
• cerebrospinal fluid leak
• cochlear implants
No comments:
Post a Comment